Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eczema drug shows promise in Mid-Stage trial

NCT ID NCT06136741

Disease control Sponsor: Nektar Therapeutics Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 21, 2026 · Updated 3 times

Summary

This study tests an experimental drug called rezpegaldesleukin for adults with moderate-to-severe eczema (atopic dermatitis). About 396 participants will receive either the drug or a placebo for 16 weeks, and those who improve may continue treatment for up to a year. The goal is to see if the drug reduces eczema severity and improves skin symptoms safely.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 396 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults (from at least 18 years of age) with AD as defined by the American Academy of Dermatology Consensus Criteria for 1 year or longer prior to screening. * AD disease severity at screening and randomization: * EASI of 16 or higher * IGA of 3 or 4 * BSA of 10% or more * Documented history, within 6 months prior to the screening visit, of either inadequate response or inadvisability of topical treatments. * Able to complete patient questionnaires. * Able and willing to comply with requested study visits and procedures. * Able and willing to provide written informed consent. Exclusion Criteria: * Prior use of systemic immune modulating therapies for AD (i.e., JAK inhibitors or biologics) * Other skin conditions that would interfere with assessment of AD * Treatment with a live (attenuated) immunization within 12 weeks prior to screening. * Men and women (of reproductive potential) unwilling to use highly effective birth control and women who are pregnant or breastfeeding. * Any malignancies or history of malignancies within 5 years prior to randomization (except for basal cell or squamous epithelial carcinomas of the skin that have been successfully treated with no evidence of metastatic disease for 3 years or cervical carcinoma in situ that has been successfully treated, with no evidence of recurrence within the 3 years prior to randomization). * Known history of, or suspected, significant current immunosuppression, including history of invasive opportunistic infections despite infection resolution or otherwise recurrent infections of abnormal frequency or prolonged duration. * Positive for human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) at screening. * Severe concomitant illness that would in the Investigator's opinion inhibit the patient's participation in the study, including for example, but not limited to, hypertension, renal disease, neurological conditions, heart failure and pulmonary disease. * Concurrent participation in any other investigational clinical study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Moderate-to-severe atopic dermatitis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Moderate-to-severe atopic dermatitis

Contacts and locations

Locations

  • Nektar Investigative Site

    Bryant, Arkansas, 72022, United States

  • Nektar Investigative Site

    Fountain Valley, California, 92708, United States

  • Nektar Investigative Site

    Los Angeles, California, 90017, United States

  • Nektar Investigative Site

    Los Angeles, California, 90025, United States

  • Nektar Investigative Site

    Los Angeles, California, 90057, United States

  • Nektar Investigative Site

    Santa Monica, California, 90404, United States

  • Nektar Investigative Site

    Hialeah, Florida, 33016, United States

  • Nektar Investigative Site

    Hollywood, Florida, 33021, United States

  • Nektar Investigative Site

    Miami, Florida, 33173, United States

  • Nektar Investigative Site

    Miami Lakes, Florida, 33014, United States

  • Nektar Investigative Site

    St. Petersburg, Florida, 33705, United States

  • Nektar Investigative Site

    Tampa, Florida, 33615, United States

  • Nektar Investigative Site

    Marietta, Georgia, 30060, United States

  • Nektar Investigative Site

    Clarksville, Indiana, 47129, United States

  • Nektar Investigative Site

    Indianapolis, Indiana, 46202, United States

  • Nektar Investigative Site

    Louisville, Kentucky, 40241, United States

  • Nektar Investigative Site

    Flint, Michigan, 48532, United States

  • Nektar Investigative Site

    Troy, Michigan, 48084, United States

  • Nektar Investigative Site

    Las Vegas, Nevada, 89106, United States

  • Nektar Investigative Site

    New York, New York, 10075, United States

  • Nektar Investigative Site

    Fairborn, Ohio, 45324, United States

  • Nektar Investigative Site

    Mayfield Heights, Ohio, 44124, United States

  • Nektar Investigative Site

    Murfreesboro, Tennessee, 37130, United States

  • Nektar Investigative Site

    Bellaire, Texas, 77401, United States

  • Nektar Investigative Site

    Cypress, Texas, 77429, United States

  • Nektar Investigative Site

    Frisco, Texas, 75034, United States

  • Nektar Investigative Site

    Spokane, Washington, 99202-1461, United States

  • Nektar Investigative Site

    Spokane, Washington, 99202, United States

  • Nektar Investigative Site

    Darlinghurst, New South Wales, 2010, Australia

  • Nektar Investigative Site

    Kogarah, New South Wales, 2217, Australia

  • Nektar Investigative Site

    Westmead, New South Wales, 2145, Australia

  • Nektar Investigative Site

    Woolloongabba, Queensland, 4102, Australia

  • Nektar Investigative Site

    Campbelltown, South Australia, 5074, Australia

  • Nektar Investigative Site

    East Melbourne, Victoria, 3002, Australia

  • Nektar Investigative Site

    Melbourne, Victoria, 3004, Australia

  • Nektar Investigative Site

    Sevlievo, Gabrovo, 5400, Bulgaria

  • Nektar Investigative Site

    Dupnitsa, Kyustendil, 2600, Bulgaria

  • Nektar Investigative Site

    Sofia, Sofia-Grad, 1407, Bulgaria

  • Nektar Investigative Site

    Sofia, Sofia-Grad, 1431, Bulgaria

  • Nektar Investigative Site

    Sofia, Sofia-Grad, 1592, Bulgaria

  • Nektar Investigative Site

    Sofia, Sofia-Grad, 1784, Bulgaria

  • Nektar Investigative Site

    Lovech, 5500, Bulgaria

  • Nektar Investigative Site

    Pleven, 5800, Bulgaria

  • Nektar Investigative Site

    Sofia, 1463, Bulgaria

  • Nektar Investigative Site

    Sofia, 1510, Bulgaria

  • Nektar Investigative Site

    Calgary, Alberta, T2J 7E1, Canada

  • Nektar Investigative Site

    Edmonton, Alberta, T6H 4J8, Canada

  • Nektar Investigative Site

    Kelowna, British Columbia, V1W 4V5, Canada

  • Nektar Investigative Site

    Surrey, British Columbia, V3V 0C6, Canada

  • Nektar Investigative Site

    Barrie, Ontario, L4M 7G1, Canada

  • Nektar Investigative Site

    Markham, Ontario, L3P 1X3, Canada

  • Nektar Investigative Site

    Peterborough, Ontario, K9J 5K2, Canada

  • Nektar Investigative Site

    Richmond Hill, Ontario, L4B 1A5, Canada

  • Nektar Investigative Site

    Toronto, Ontario, M3H 5Y8, Canada

  • Nektar Investigative Site

    Toronto, Ontario, M4W 2N2, Canada

  • Nektar Investigative Site

    Québec, Quebec, G1W 4R4, Canada

  • Nektar Investigative Site

    Ivanić-Grad, 10310, Croatia

  • Nektar Investigative Site

    Brno, 602 00, Czechia

  • Nektar Investigative Site

    Pardubice, 530 02, Czechia

  • Nektar Investigative Site

    Prague, 100 34, Czechia

  • Nektar Investigative Site

    Prague, 150 00, Czechia

  • Nektar Investigative Site

    Augsburg, Bavaria, 86150, Germany

  • Nektar Investigative Site

    Erlangen, Bavaria, 91054, Germany

  • Nektar Investigative Site

    Bad Bentheim, Lower Saxony, 48455, Germany

  • Nektar Investigative Site

    Mainz, Rhineland-Palatinate, 55131, Germany

  • Nektar Investigative Site

    Leipzig, Saxony, 4103, Germany

  • Nektar Investigative Site

    Berlin, 10789, Germany

  • Nektar Investigative Site

    Berlin, 13353, Germany

  • Nektar Investigative Site

    Darmstadt, 64283, Germany

  • Nektar Investigative Site

    Frankfurt, 60590, Germany

  • Nektar Investigative Site

    Lübeck, 23538, Germany

  • Nektar Investigative Site

    Gyula, Bekes County, 5700, Hungary

  • Nektar Investigative Site

    Wroclaw, Lower Silesian Voivodeship, 50-220, Poland

  • Nektar Investigative Site

    Wroclaw, Lower Silesian Voivodeship, 50-381, Poland

  • Nektar Investigative Site

    Wroclaw, Lower Silesian Voivodeship, 51-685, Poland

  • Nektar Investigative Site

    Warsaw, Masovian Voivodeship, 00-874, Poland

  • Nektar Investigative Site

    Warsaw, Masovian Voivodeship, 02-672, Poland

  • Nektar Investigative Site

    Warsaw, Masovian Voivodeship, 02-953, Poland

  • Nektar Investigative Site

    Rzeszów, Podkarpackie Voivodeship, 35-055, Poland

  • Nektar Investigative Site

    Gdansk, Pomeranian Voivodeship, 80-382, Poland

  • Nektar Investigative Site

    Gdansk, Pomeranian Voivodeship, 80-546, Poland

  • Nektar Investigative Site

    Gdynia, Pomeranian Voivodeship, 81-537, Poland

  • Nektar Investigative Site

    Częstochowa, 42-202, Poland

  • Nektar Investigative Site

    Iława, 14-200, Poland

  • Nektar Investigative Site

    Katowice, 40-040, Poland

  • Nektar Investigative Site

    Krakow, 30-727, Poland

  • Nektar Investigative Site

    Krakow, 31-011, Poland

  • Nektar Investigative Site

    Lodz, 90-127, Poland

  • Nektar Investigative Site

    Lodz, 90-436, Poland

  • Nektar Investigative Site

    Poznan, 60-702, Poland

  • Nektar Investigative Site

    Szczecin, 71-500, Poland

  • Nektar Investigative Site

    Tarnów, 33-100, Poland

  • Nektar Investigative Site

    Warsaw, 01-142, Poland

  • Nektar Investigative Site

    Warsaw, 02-507, Poland

  • Nektar Investigative Site

    Warsaw, 02-962, Poland

  • Nektar Investigative Site

    Wroclaw, 50-566, Poland

  • Nektar Investigative Site

    Wroclaw, 51-503, Poland

  • Nektar Investigative Site

    Alicante, 3010, Spain

  • Nektar Investigative Site

    Córdoba, 14004, Spain

  • Nektar Investigative Site

    Granada, 18014, Spain

  • Nektar Investigative Site

    Seville, 41009, Spain

  • Nektar Investigative Site

    Zaragoza, 50009, Spain

  • Nektar Investigative Site 5701

    Zagreb, City of Zagreb, 10000, Croatia

  • Nektar Investigative Site 5703

    Zagreb, City of Zagreb, 10000, Croatia

  • Nektar Investigator Site

    Augsburg, Bavaria, 86179, Germany

  • Nektar Investigator Site

    München, 80337, Germany

  • Nektar Investigator Site

    Krakow, 30-033, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.